Abstract
Background and Objectives: Hepatic steatosis is associated with an increased risk of liver-related morbidity and mortality. Although numerous studies have reported associations between depression, obesity, metabolic syndrome, and cardiovascular disease, the relationship between depression and hepatic steatosis has not yet been fully elucidated. Moreover, obesity is a shared risk factor for hepatic steatosis and depression; however, few studies have adequately adjusted for obesity as a potential confounder. In this study, we investigated the association between depression and hepatic steatosis stratified by obese and non-obese status. Materials and Methods: This study used data from the Korean National Health and Nutrition Examination Survey, conducted by the Korean Ministry of Health and Welfare between 2010 and 2019, which was a cross-sectional and nationally representative study of non-institutionalized civilians using a stratified, multistage, clustered probability sampling design. Multivariate logistic regression analyses were conducted to evaluate the association between depression and hepatic steatosis in the groups stratified by obese status. Results: Of 80,861 participants, data from 45,307 were included in the analysis. The prevalence of non-obese and obese hepatic steatosis was 3.1% and 19.3%, respectively, and the prevalence of diagnosed depression was 4.6%. Individuals with hepatic steatosis showed less favorable metabolic profiles, including higher rates of diabetes and elevated liver enzyme levels. Those with depression were older, predominantly female, and had lower socioeconomic status. After fully adjusting for confounding factors, multivariate logistic regression analysis showed that non-obese hepatic steatosis was significantly associated with an increased risk of depression, and obese hepatic steatosis was significantly associated with suicidal ideation and attempts. Conclusions: This study suggests a significant association between depression and hepatic steatosis with and without obese status. Given the significant impact of hepatic steatosis on depression outcomes, healthcare providers should screen patients with hepatic steatosis for depression and provide appropriate treatment as needed.